STOCK TITAN

Valion Bio estimates Q3 net loss of about $16.2M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Valion Bio, Inc. (VBIO) expects to file its Form 10-Q for the quarter ended September 30, 2026 within the five-calendar-day extension period provided by Rule 12b-25, after needing additional time to compile, review and finalize its financial statements and related disclosures.

Based on preliminary information, Valion estimates net losses of approximately $16.2 million for the three months and $29.5 million for the nine months ended September 30, 2026, versus approximately $2.6 million and $6.0 million in the comparable 2025 periods. Valion attributes the increase primarily to write-downs for long-lived asset and goodwill impairment, higher research and development and selling, general and administrative expenses, and interest expense. The estimates remain subject to review and finalization.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointQ3 net loss: approximately $16.2 million, versus $2.6 million in 2025.
Net loss, three months ended September 30, 2026 Approximately $16.2 million Preliminary estimate
Net loss, nine months ended September 30, 2026 Approximately $29.5 million Preliminary estimate
Net loss, corresponding three months in 2025 Approximately $2.6 million Comparative period
Net loss, corresponding nine months in 2025 Approximately $6.0 million Comparative period
impairment of long-lived assets and goodwill financial
"write-downs associated with impairment of long-lived assets and goodwill"
Rule 12b-25 regulatory
"five-calendar-day extension period provided by Rule 12b-25"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.
contract development and manufacturing organization technical
"costs associated with the Company’s contract development and manufacturing organization operations"
A contract development and manufacturing organization (CDMO) is a specialized service provider that helps other companies design, test, produce and package drugs or medical products on a hired basis. Think of it as an outsourced factory and R&D partner that lets a company scale production without building its own plants. Investors watch CDMO relationships because they affect a drug’s time-to-market, manufacturing costs, supply reliability and overall project risk, all of which influence future revenue and valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What net loss does VBIO expect for the third quarter and first nine months of 2026?

Valion Bio estimates preliminary net losses of approximately $16.2 million for the three months and $29.5 million for the nine months ended September 30, 2026. The comparable 2025 losses were approximately $2.6 million and $6.0 million, respectively; the estimates remain subject to review and finalization.

Why is VBIO's Form 10-Q late?

Valion Bio says it needs additional time to complete the compilation, review and finalization of the financial statements and related disclosures for its Form 10-Q. It expects to file within the five-calendar-day extension period provided by Rule 12b-25.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

SEC File Number 001-41052

 

(Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

For Period Ended: September 30, 2026

 

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: __________________________

 

Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

VALION BIO, INC.
Full Name of Registrant
 
TIVIC HEALTH SYSTEMS, INC.
Former Name if Applicable
 
1305 E. Houston St., Building 1, Suite 311
Address of Principal Executive Office (Street and Number)
 
San Antonio, Texas 78205
City, State and Zip Code

 

 

 

 

   

 

 

PART II — RULES 12B-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

☒ (a) The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
   
☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date: and
   
☐ (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Company is unable to complete its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 within the prescribed time period without unreasonable effort or expense because it requires additional time to complete the compilation, review and finalization of the financial statements and related disclosures to be included in the Form 10-Q. The Company expects to file the Form 10-Q within the five-calendar-day extension period provided by Rule 12b-25.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Lisa Wolf   888   276 - 6888
(Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

 

Yes ☒ No ☐

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

Yes ☒ No ☐

 

Based on currently available information, the Company expects to report a net loss of approximately $16.2 million and $29.5 million for the three and nine months ended September 30, 2026, respectively, compared with approximately $2.6 million and $6.0 million for the corresponding periods in 2025. The increase was primarily attributable to write-downs associated with impairment of long-lived assets and goodwill, along with higher research and development and selling, general and administrative expenses, including costs associated with the Company’s contract development and manufacturing organization operations, and interest expense. These estimates are preliminary and subject to completion of the Company’s review and finalization of the Form 10-Q.

 

 

 2 

 

 

VALION BIO, INC.
(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

       
Date: November 16, 2026 By: /s/ Lisa Wolf  
    Name: Lisa Wolf  
    Title: Chief Financial Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

Keep reading